Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 17/20 | 0.48 |
| ▸ | ACE | P12821 | 9/20 | 0.48 |
| ▸ | EMG1 | Q92979 | 2/20 | 0.46 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17011362 | 0.82 | ACE (0.60) | MMEACEEMG1MMEL1 | |
| SCHEMBL24022288 | 0.82 | ACE (0.60) | MMEACEEMG1MMEL1 | |
| SCHEMBL19840281 | 0.82 | ACE (0.60) | MMEACEEMG1MMEL1 | |
| SCHEMBL19190564 | 0.82 | MME (0.58) | MMEACEMMEL1 | |
| SCHEMBL14902429 | 0.81 | MME (0.72) | MMEACEMMEL1 | |
| SCHEMBL18597756 | 0.81 | MME (0.72) | MMEACEMMEL1 | |
| SCHEMBL19840282 | 0.80 | MME (0.63) | MMEACEMMEL1 | |
| SCHEMBL19690456 | 0.80 | MME (0.63) | MMEACEMMEL1 | |
| SCHEMBL18724941 | 0.80 | MME (0.63) | MMEACEMMEL1 | |
| SCHEMBL17011360 | 0.80 | MME (0.63) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885EMG1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.